Blog - Page 2 of 5720 - QualityStocks

TuesdayAug 25, 2026 9:00 am

Nano-X Imaging Ltd. (NASDAQ: NNOX) Is ‘One to Watch’

The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation. Nanox is expanding its commercial reach through its U.S. commercial activities and collaboration with healthcare organizations. First-quarter 2026 revenue increased to $4.3 million from $2.8 million in the prior-year period, with contributions from teleradiology, imaging systems, OEM services, AI, software and Health IT. Nanox has secured FDA clearance for Nanox.ARC, Nanox.ARC X and three Nanox.AI medical imaging solutions, while its commercial and clinical activities involve organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women’s…

MondayAug 24, 2026 11:15 am

MindWave Innovations Inc. (NYSE American: APUS) Is Helping Corporations Hold, Manage, and Generate Risk-Aware Yield on Bitcoin Reserves

MindWave Innovations is developing institutional-grade digital asset infrastructure designed to help corporations and institutions hold, manage and generate yield from Bitcoin reserves while combining traditional financial controls with blockchain efficiency. The company is expanding access to its ecosystem, with its native $NILA token now available to eligible U.S. users through Webot, providing a regulated pathway into the broader MindWaveDAO ecosystem. The expansion is expected to continue with the October 2026 launch of MindChain, an independent Layer 2 blockchain that MindWave describes as the world's first fully insured blockchain and a foundation for broader ecosystem development and real-world asset tokenization. As…

MondayAug 24, 2026 10:55 am

QualityStocksNewsBreaks – Residential Equity Strategy Gains New Context with TYTL’s Reg D Filing

Beeline Holdings (NASDAQ: BLNE) is developing a residential equity strategy designed to give qualified homeowners access to liquidity without taking on additional debt, and a recent Regulation D filing by TYTL Corp. provides new details on the potential capital infrastructure that could support that model. TYTL filed a new Form D offering of up to $1 billion in digital securities available for sale to support the unique equity product under Rule 506(c) of Regulation D. The filing identifies the securities as pooled investment fund interests as well as forward purchase commitments and Reg D digital securities issuable in satisfaction of those commitments.…

MondayAug 24, 2026 10:30 am

Frontieras North America Inc. Advances a Low-Sulfur Industrial Carbon That Heavy Industry Is Already Looking For

The challenge for steel and other heavy industries is not finding carbon; it is finding carbon that performs reliably without introducing sulfur into the process. FASCarbon(TM) is the solid carbon output of Frontieras's FASForm(TM) process, a continuous solid carbon fractionation system that thermally cracks coal without combustion. FASCarbon's low sulfur content makes it a direct substitute for higher-grade, more expensive carbon inputs in steelmaking and industrial heating applications. Coal has always been valued for what it produces when burned. Frontieras North America has built a business around what it produces when it isn't burned. The company's FASForm(TM) process fractionates coal into…

MondayAug 24, 2026 10:20 am

QualityStocksNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) Reports First S-K 1300 Indicated Resource, Hybrid Mining Estimate for Sarfartoq

Greenland Mines (NASDAQ: GRML) announced an independently prepared S-K 1300 Technical Report Summary (“TRS”) for its Sarfartoq Nd-Pr Rare Earths Project in southwest Greenland, marking the first time the project has reported a portion of its resource in the Indicated Mineral Resource category under an SEC-recognized reporting standard. The report, prepared by Tetra Tech Canada Inc. and GeoSim Services Inc. with an effective date of July 31, 2026, also provides Sarfartoq’s first combined open pit and underground resource estimate. Under the hybrid scenario, which Greenland Mines considers the most representative view of the project’s development potential, Sarfartoq contains an Indicated…

MondayAug 24, 2026 9:45 am

From Evaluation to Deployment: SPARC AI Inc.’s (CSE: SPAI) (OTCQB: SPAIF) Push into U.S. Public Safety with GPS-Independent Drone Technology

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. SPARC AI is expanding its push into the U.S. public safety market with GPS-independent target acquisition and navigation technology designed for drones and other autonomous systems. The company has established a dedicated U.S. Federal and Public Safety team focused on customer engagement, demonstrations, evaluations, systems integration and government procurement pathways. The new team is intended to help move Overwatch from field evaluations toward operational adoption across law enforcement, border security, search and rescue, disaster response and critical-infrastructure missions. SPARC AI (CSE: SPAI) (OTCQB: SPAIF)…

MondayAug 24, 2026 9:10 am

QualityStocksNewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Featured in AINewsWire Editorial on Expanding AI Infrastructure Investment

AZIO AI Holdings (NASDAQ: AZIO) is featured in an AINewsWire editorial examining the growing investment in artificial intelligence infrastructure and the increasing importance of land, power and connectivity alongside computing hardware. The editorial highlights AZIO’s Atlas One, the first named development phase of Project Atlas, a South Texas compute campus spanning more than 548 acres and designed for up to 500 MW of planned behind-the-meter capacity. The article notes that roughly 6 MW of off-grid power has been deployed to support modular data centers at the site and highlights the company’s Master Services Agreement with AT&T for enterprise fiber connectivity,…

MondayAug 24, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct the preclinical validation needed to determine the program’s next development steps. VXA-222 uses an “AND-gate” approach designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload. The company has separately filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms while expanding protection around antibody conjugation and payload technologies. The company is building a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel…

FridayAug 21, 2026 3:45 pm

QualityStocksNewsBreaks – Market Street Capital Inc. Helps Founders Navigate Expanding Private Credit Landscape

Market Street Capital was featured in a recent article that discusses how the expanding private credit sector is giving middle-market founders more options when evaluating debt and equity financing. The article explores the long-term implications of each approach, noting that debt can preserve ownership and provide cost-efficient capital for established businesses with predictable cash flows, while equity can offer greater flexibility for transformational initiatives but comes with ownership dilution and potential changes in governance. As traditional bank lending remains less accessible to some middle-market companies, private credit has emerged as an increasingly important source of financing through structures such as senior…

FridayAug 21, 2026 3:30 pm

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) recently received favorable Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) regarding the development strategy for its lead BiTAC-TCE cancer therapy, providing regulatory guidance on the program’s biological rationale, pharmacokinetics and planned non-clinical safety studies ahead of potential clinical trials. The company views the feedback as an early regulatory validation that could reduce development uncertainty and clarify the path toward the clinic. VERAXA’s lead candidate previously produced encouraging preclinical results presented at the 2026 AACR Annual Meeting, where the company reported selective targeting of cancer cells carrying two biomarkers while sparing cells with only one, potentially improving the…

Site Search

Company Search